Results 31 to 40 of about 47,139 (255)

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome ...
Ahmed M. Altibi, Fares Ghanem, Yuanzi Zhao, Miriam Elman, Joaquin Cigarroa, Babak Nazer, Howard K. Song, Ahmad Masri   +7 more
doaj   +1 more source

Incremental Prognostic Utility of Left Ventricular Global Longitudinal Strain in Hypertrophic Obstructive Cardiomyopathy Patients and Preserved Left Ventricular Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn obstructive hypertrophic cardiomyopathy patients with preserved left ventricular (LV) ejection fraction, we sought to determine whether LV global longitudinal strain (LV‐GLS) provided incremental prognostic utility.
Albree Tower‐Rader, Jorge Betancor, Zoran B. Popovic, Kimi Sato, Maran Thamilarasan, Nicholas G. Smedira, Harry M. Lever, Milind Y. Desai   +7 more
doaj   +1 more source

Availability and Utilization of Automated External Defibrillators in New York State Schools

Frontiers in Pediatrics, 2021
Background: Use of automated external defibrillators (AEDs) in out-of-hospital cardiac arrests (OHCAs) improve survival. Professional health organizations recommend that AEDs be available in crowded places, including schools but currently only 18 US ...
Milla Arabadjian, Milla Arabadjian, Stephanie Serrato, Mark V. Sherrid   +3 more
doaj   +1 more source

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown.
Milla E. Arabadjian, Maria C. Reuter, Alexandra Stepanovic, Mark V. Sherrid, Daniele Massera   +4 more
doaj   +1 more source

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy

Scientific Reports, 2021
Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM).
Styliani Vakrou, Yamin Liu, Li Zhu, Gabriela V. Greenland, Bahadir Simsek, Virginia B. Hebl, Yufan Guan, Kirubel Woldemichael, Conover C. Talbot, Miguel A. Aon, Ryuya Fukunaga, M. Roselle Abraham   +11 more
doaj   +1 more source

Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome

Reviews in Cardiovascular Medicine, 2023
Despite considerable interest in the syndrome of acute left ventricular (LV) ballooning, its pathophysiology has remained ill-defined. In this review, we explore observational data describing two etiologies of acute LV ballooning: neurohumoral classic ...
Arushi Singh, Louai Razzouk, Daniele Massera, Mark V. Sherrid   +3 more
doaj   +1 more source

Automated segmentation of left ventricular myocardium using cascading convolutional neural networks based on echocardiography

AIP Advances, 2021
Quickly and accurately segmenting the left ventricular (LV) myocardium from ultrasound images and measuring the thickness of the interventricular septum and LV wall play an important role in hypertrophic cardiomyopathy.
Shenghan Ren, Yongbing Wang, Rui Hu, Lei Zuo, Liwen Liu, Heng Zhao   +5 more
doaj   +1 more source

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock, Yousef H. Bader, Martin S. Maron, Ethan J. Rowin, Mark S. Link   +4 more
doaj   +1 more source

Probing Subcellular Nanostructure of Engineered Human Cardiomyocytes in 3D Tissue [PDF]

, 2021
The structural and functional maturation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is essential for application to pharmaceutical testing, disease modeling, and ultimately therapeutic use. Multicellular 3D-tissue platforms have improved functional maturation of hiPSC-CMs, but probing cardiac contractile properties ...
arxiv   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid, Daniel G. Swistel, Iacopo Olivotto, Maurizio Pieroni, Omar Wever‐Pinzon, Katherine Riedy, Richard G. Bach, Mustafa Husaini, Sharon Cresci, Alex Reyentovich, Daniele Massera, Martin S. Maron, Barry J. Maron, Bette Kim   +13 more
doaj   +1 more source